In the treatment of Alzheimer s disease (AD), health care professionals are in dire need of clinical confidence in the evidence-based potential of novel disease-modifying therapeutic options. Several promising classes of emerging agents such as amyloid-targeting humanized monoclonal antibodies (mAbs), incretin-based therapies, and others are poised to shift the paradigm of diagnosis, management, and treatment of MCI and early dementia in AD. These emerging therapies require that clinicians and multidisciplinary teams be up to date on safety, efficacy, and mechanisms of action to optimize standards of care for patients with AD. In the third activity of this three-part CME Outfitters Snack series, expert faculty will guide learners through identifying the latest data on safety, efficacy, and mechanisms of current and emerging disease-modifying therapeutic options for the management of AD.
- Provider:CME Outfitters, LLC
- Activity Link: https://www.cmeoutfitters.com/activity/recent-and-emerging-therapeutic-options-for-alzheimers-disease/
- Start Date: 2024-05-28 05:00:00
- End Date: 2024-05-28 05:00:00
- Credit Details: IPCE Credits: 0.5 hours
AAPA Category 1 Credit™️: 0.5 hours
AMA PRA Category 1 Credit™️: 0.5 hours
Nursing: 0.5 hours
Pharmacy: 0.5 hours - MOC Credit Details: ABIM - 0.5 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: Novo Nordisk (Any division) - Amount: 0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Internal Medicine